STAT3 and hepatocellular carcinoma: One example is TTI-101, a novel orally delivered small molecule inhibitor of STAT3 utilized in clinical trials initiated to address STAT3-driven disease in hepatocellular carcinoma (NCT05440708) and metastatic breast cancer (NCT05384119).